Changeflow GovPing Pharma & Drug Safety NX-5948 versus pirtobrutinib relapsed refractor...
Routine Notice Added Final

NX-5948 versus pirtobrutinib relapsed refractory CLL SLL trial

Favicon for clinicaltrials.gov ClinicalTrials.gov
Detected April 7th, 2026
Email

Summary

ClinicalTrials.gov registered a new Phase 3 randomized trial (NCT07516093) comparing NX-5948 to pirtobrutinib in adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The single-arm study will evaluate efficacy and safety endpoints.

View original document View source feed page

What changed

A clinical trial registration was added to ClinicalTrials.gov for a randomized study comparing NX-5948, a novel BTK degrader, against pirtobrutinib in patients with relapsed or refractory CLL/SLL who have received at least two prior lines of therapy. The trial will assess overall response rate and other efficacy measures.

Healthcare providers treating CLL/SLL patients should be aware of this comparative trial for potential referral opportunities. Clinical investigators may consider protocol requirements when evaluating study participation.

What to do next

  1. Monitor for trial enrollment updates
  2. Review inclusion/exclusion criteria for patient referrals
  3. Track primary completion date milestones

Source document (simplified)

Show glossary

Related changes

Favicon for clinicaltrials.gov Acupuncture and Chinese herbal fumigation for chronic neck pain, Malaysia
Routine Apr 07, 2026 • ClinicalTrials.gov • Pharma & Drug Safety
Favicon for clinicaltrials.gov Clinical Trial Study NCT07515573
Routine Apr 07, 2026 • ClinicalTrials.gov • Pharma & Drug Safety
Favicon for clinicaltrials.gov Clinical Trial - HPV Oropharyngeal Cancer, Medical University of South Carolina
Routine Apr 07, 2026 • ClinicalTrials.gov • Pharma & Drug Safety
Favicon for changeflow.com Oregon SB1598 Health Services Access and Coverage Requirements
Priority review Apr 07, 2026 • Oregon Legislative Events • Government General
Favicon for www.irs.gov 8 Arrested in Healthcare Fraud Takedown Involving Hospice Owners
Urgent Apr 07, 2026 • IRS Criminal Investigation • Banking & Finance
Favicon for www.regulations.gov FDA Administrative Practices and Procedures Information Collection Comment Request
Routine Apr 07, 2026 • Regs.gov: Food and Drug Administration • Healthcare

Source

Favicon for clinicaltrials.gov
ClinicalTrials.gov clinicaltrials.gov/ct2/results/rss.xml
Pharma & Drug Safety
Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
NIH-NLM
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07516093
Docket
NCT07516093

Who this affects

Applies to
Clinical investigators Healthcare providers Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Clinical trial registration Oncology research
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Pharmaceuticals Public Health

Browse Categories

Agriculture & Food Safety 63 AI Regulation 3 Banking & Finance 287 Consumer Protection 44 Courts & Legal 361 Data Privacy & Cybersecurity 74 Defense & National Security 52 Education 20 Energy 101 Environment 85 Environmental Permits 1 Environmental Regulation 13 Government & Legislation 278 Healthcare 136 Housing 16 Immigration 9 Insurance 58 Labor & Employment 113 Legislative 1 Pharma & Drug Safety 104 Public Health 3 Securities & Markets 104 Securities Regulation 14 Tax 66 Telecom & Technology 47 Trade & Sanctions 124 Transportation 57

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ClinicalTrials.gov publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.